C-A3TNautologous stem cells, angiogenic cell precursors, ischemia
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Support reproducible, quality-controlled, consistent preparation of ACP-01 from patient blood in regulated research environments.
Proprietary autologous cell processing platform for deriving angiogenic cell precursors from a patient's own blood.
Company site analysis describes the platform as supporting reproducibility, quality control, and consistent ACP-01 preparation.
Assess whether autologous angiogenic cell precursor implantation can improve cardiac function and quality of life in ischemic and non-ischemic cardiomyopathy.
Transcatheter intramyocardial or intracoronary implantation of autologous ACP-01 cells; outcomes analysis of treated cardiomyopathy patients; publications are linked downstream through company_project_publications.
2023 Stem Cell Research & Therapy outcomes analysis of 74 treated patients, with 54 meeting inclusion requirements.
Reported serious adverse events included one death, ventricular tachycardia requiring cardioversion, and respiratory infection. LVEF improved in ischemic and non-ischemic cardiomyopathy subgroups, and 33 of 50 patients reported quality-of-life improvement.
Evaluate autologous angiogenic cell precursor therapy for ischemic limb disease, including critical limb ischemia, chronic limb threatening ischemia, peripheral arterial disease, ulcer burden, amputation risk, and mortality in patients without revascularization options.
Intramuscular injection of blood-derived autologous angiogenic cell precursors in a randomized, placebo-controlled clinical trial; publications are linked downstream through company_project_publications.
Phase 2 ACP CLI trial reported in Journal of Vascular Surgery in 2023; clinical trial record NCT02551679 describes efficacy and safety evaluation in no-option critical limb ischemia.
Site-listed publications report decreases in ulcer size, amputation, and death rate in re-examined phase II ACP NO-CLI data, and a 4.5-year clinical update for CLI patients with no revascularization options.
Treat severe angina pectoris using autologous blood-borne angiogenic cell precursors in ischemic cardiovascular disease.
Intracoronary injection of autologous blood-borne angiogenic cell precursors; publications are linked downstream through company_project_publications.
Site-listed clinical research publication on treatment of severe angina pectoris using intracoronarily injected autologous blood-borne angiogenic cell precursors.